Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

Authors

  • Stefan Faderl MD,

  • Alessandra Ferrajoli MD,

  • William Wierda MD, PhD,

  • Susan O'Brien MD,

  • Susan Lerner MD,

  • Michael J. Keating MD

Errata

This article corrects:

  1. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence Volume 116, Issue 10, 2360–2365, Article first published online: 11 March 2010

No abstract is available for this article.

Ancillary